AI Article Synopsis

  • The study explores how atrial fibrillation (AF) affects the heart and investigates the impact of the drug vericiguat on heart structure and function, noting its unclear effects on AF specifically.
  • Researchers conducted experiments on rabbits and heart cells, assessing various factors such as heart function, protein expression, and calcium levels.
  • The results indicate that vericiguat can improve heart structure, reduce fibrosis, and help maintain heart rhythm, suggesting it could be a potential treatment for AF.

Article Abstract

The molecular etiology of atrial fibrillation (AF) and its treatment are poorly understood. AF involves both electrical and structural features. Vericiguat can ameliorate cardiac remodeling in heart failure. The effects of vericiguat on AF, however, are unclear. Here, the actions of vericiguat on atrial structural and electrical remodeling in AF and its possible mechanisms were investigated. Thirty-six rabbits were randomly allocated to four groups, namely, sham, RAP (pacing with 600 beats/min over three weeks), vericiguat-treated (three weeks' pacing plus daily oral dose of 1.5 mg/kg of vericiguat), and vericiguat-treated only. HL-1 cells received rapid pacing with or without vericiguat. Parameters including electrophysiology, echocardiography, histology, Ca levels, and I density, as well as levels of TRPC6, CaN, NFAT4, p-NFAT4, Cav1.2, collagen I, collagen III, and ST2 were measured. Significant changes of above proteins expression level, circulating biochemical indices, Ca concentrations, and I density in both animals and cell models, these effects were significantly restored by vericiguat. Vericiguat also reversed the enlarged atrium and significantly reduced myocardial fibrosis, together with preventing reduced atrial effective refractory periods (AERPs) and AF induction rate. Vericiguat thus ameliorated AF-associated structural and electrical remodeling. These findings suggest the potential of vericiguat for treating AF.

Download full-text PDF

Source
http://dx.doi.org/10.1177/10742484231185252DOI Listing

Publication Analysis

Top Keywords

vericiguat
10
electrical structural
8
atrial fibrillation
8
structural electrical
8
electrical remodeling
8
vericiguat reduces
4
electrical
4
reduces electrical
4
structural
4
remodeling
4

Similar Publications

Novel Therapies to Reduce Rehospitalization Risk in Worsening Heart Failure: Systematic Review and Network Meta-Analysis.

JACC Adv

January 2025

Heart Failure Clinics, Instituto do Coracao, Hospital das Clínicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Sao Paulo, Brazil.

Background: Worsening heart failure (WHF) challenges health care with frequent rehospitalizations and reduced quality of life for patients. Despite therapeutic advances, high rehospitalization risks highlight the urgent need for new treatments.

Objectives: This study evaluated the effectiveness of initiating novel therapies during hospitalization or vulnerable phase for WHF patients to reduce rehospitalization risks and determine the optimal treatment sequence.

View Article and Find Full Text PDF

Characterizing Vericiguat Treatment in Heart Failure: A Multicenter Real-World Study in China.

Rev Cardiovasc Med

December 2024

Department of Cardiology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, 230001 Hefei, Anhui, China.

Background: Real-world data on the clinical benefit of vericiguat are currently limited. This multicenter, real-world study was conducted to evaluate the clinical characteristics and therapeutic effects of vericiguat in real-world settings.

Methods: This study analyzed heart failure (HF) patients who initiated vericiguat treatment from September 2022 to August 2023 across nine hospitals in the Anhui Province, China.

View Article and Find Full Text PDF

Objective: This study aimed to investigate the safety of vericiguat in patients with coronary artery disease.

Methods: We conducted a comprehensive literature review of the PubMed, ClinicalTrials.gov, and Cochrane Library databases up to 27 March 2024.

View Article and Find Full Text PDF

Analysis of vericiguat via ion-pairing with eosin Y as a spectrofluorimetric and spectrophotometric probe: Application to content uniformity test.

Spectrochim Acta A Mol Biomol Spectrosc

November 2024

Pharmaceutical Analytical Chemistry Department, Faculty of Pharmacy, Beni-Suef University, Alshaheed Shehata Ahmed Hegazy St., Beni-Suef 62511, Egypt.

Using spectroscopy, quick and sensitive analytical methods based on Eosin Y ion pairing were developed and assessed in order to determine vericiguat with high selectivity and sensitivity. The drug is used for treating symptomatic chronic heart failure (HF), The quenching impact of vericiguat on the Eosin Y's fluorescence at a pH 3.3, in 0.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!